Gamma oscillations in the mPFC: A potential predictive biomarker of depression and antidepressant effects

Prog Neuropsychopharmacol Biol Psychiatry. 2024 Feb 8:129:110893. doi: 10.1016/j.pnpbp.2023.110893. Epub 2023 Nov 8.

Abstract

Gamma oscillations have attracted much attention in the field of mood disorders, but their role in depression remains poorly understood. This study aimed to investigate whether gamma oscillations in the medial prefrontal cortex (mPFC) could serve as a predictive biomarker of depression. Chronic restraint stress (CRS) or lipopolysaccharide (LPS) were used to induce depression-like behaviors in mice; local field potentials (LFPs) in the mPFC were recorded by electrophysiological techniques; We found that both CRS and LPS induced significant depression-like behaviors in mice, including increasing immobility durations in the forced swimming test (FST) and tail suspension test (TST) and increasing the latency to feed in the novelty-suppressed feeding test (NSFT). Electrophysiological results suggested that CRS and LPS significantly reduced low and high gamma oscillations in the mPFC. Furthermore, a single injection of ketamine or scopolamine for 24 h significantly increased gamma oscillations and elicited rapid-acting antidepressant-like effects. In addition, fluoxetine treatment for 21 days significantly increased gamma oscillations and elicited antidepressant-like effects. Taken together, our findings suggest that gamma oscillations are strongly associated with depression, yielding new insights into investigating the predictive biomarkers of depression and the time course of antidepressant effects.

Keywords: Antidepressants; Depression; Gamma oscillations; Ketamine; mPFC.

MeSH terms

  • Animals
  • Antidepressive Agents / pharmacology
  • Antidepressive Agents / therapeutic use
  • Biomarkers
  • Depression* / drug therapy
  • Fluoxetine / pharmacology
  • Fluoxetine / therapeutic use
  • Lipopolysaccharides*
  • Mice

Substances

  • Lipopolysaccharides
  • Antidepressive Agents
  • Fluoxetine
  • Biomarkers